C
CellSeed EuropeR.L.
CellSeed develops regenerative medicine products primarily in Japan and Europe
About CellSeed EuropeR.L.
CellSeed Inc., established in May 2001, is a Japanese firm operating in the regenerative medicine sector. The company leverages a proprietary technology known as "Cell Sheet Engineering," which was developed by Professor Teruo Okano at Tokyo Women's Medical University. This technology utilizes temperature-responsive polymers to culture and harvest cells in sheet form without the need for enzymes that can damage the tissue. The current President and CEO is Setsuko Hashimoto, Ph.D.
The company's business model is centered on the commercialization of regenerative medicine products and related services. It operates through two main segments: the Cell Sheet Regenerative Medicine Business and the Cell Cultureware Business. The regenerative medicine arm focuses on developing treatments for conditions like esophageal and knee cartilage damage. Clinical trials for an epithelial cell sheet for esophageal regeneration began in Japan in 2016. The firm is also advancing allogeneic chondrocyte sheets for knee osteoarthritis, with a Phase 3 clinical trial notification submitted in September 2023.
CellSeed's revenue is generated through multiple streams. A significant part comes from providing Contract Development and Manufacturing Organization (CDMO) services to research institutions and biotech firms. For instance, they manufacture autologous chondrocyte sheets for Tokai University's Advanced Medical Care B program. Another income source is the sale of their specialized cell cultureware, such as the UpCell®, RepCell®, and HydroCell® product lines, to researchers globally. The company collaborates with research institutes and seeks global distribution partners for its laboratory ware. CellSeed was listed on the JASDAQ market in 2010 and transitioned to the Tokyo Stock Exchange's Growth Market in 2022.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2014
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Mar 2014 | $3.9M | — | Whiz Partners | — |
| IPO✓Exit | Jan 2014 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for CellSeed EuropeR.L. is 12K monthly website visits, down 7.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CellSeed EuropeR.L. in the Basel ecosystem
The CellSeed EuropeR.L. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Whiz Partners
Other known investors3 additional known investors
Fast Track Initiative
Nippon Venture Capital
Nissay Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about CellSeed EuropeR.L. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CellSeed EuropeR.L.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









